Fewer Proprietary Drug Names Rejected With FDA, Industry On Same Page
This article was originally published in The Tan Sheet
After several false starts, FDA and the pharma industry appear to be on the same page about vetting potential brand names for new drugs. FDA’s rate of rejecting proposed brand names has dropped from 50% or higher when the decade began to about 25%, according to Office of Surveillance and Epidemiology data.
You may also be interested in...
The trade group recommends FDA write a separate proprietary name guidance for OTC drugs. FDA’s draft guidance also renders useless OTC manufacturers’ expertise in conducting tests to determine whether consumers safely self-select nonprescription drugs based on labeling, CHPA says in comments.
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.